CO-EXOLAUNCH
10.7.2024 08:02:26 CEST | Business Wire | Press release
Exolaunch, the global leader in launch mission management, integration, and satellite deployment services, proudly announced the successful deployment of four satellites aboard Arianespace’s Ariane 6 maiden flight. The liftoff occurred on Tuesday, July 9 at 1600 GFT from the Guiana Space Centre, also known as Europe's Spaceport, in Kourou, French Guiana. Representing customers ESA, NASA, and Spacemanic, this mission highlights Exolaunch’s crucial role in broadening access to space and supporting new launch vehicle providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709995719/en/
The historic Ariane 6 liftoff occurred on Tuesday, July 9 at 1600 GFT from the Guiana Space Centre, also known as Europe's Spaceport, in Kourou, French Guiana. Photo credits: ESA, Arianespace, CNES.
This historic launch featured ESA’s ISTSat-1 and 3Cat-4, NASA’s CURIE, and Spacemanic’s GRBBeta satellites. The successful deployment of these satellites underscores Exolaunch’s commitment to facilitating groundbreaking scientific research and technological advancements through reliable and innovative satellite deployment solutions.
ESA’s ISTSat-1, developed by students at the Instituto Superior Técnico in Lisbon, aims to demonstrate ADS-B technology, validating detection capabilities and assessing antenna and receiver performance for receiving messages from commercial aircraft. 3Cat-4, a CubeSat from Universitat Politécnica de Catalunya, features a flexible microwave payload technology demonstrator with scientific objectives related to GNSS for Earth observation and AIS receiver validation.
NASA’s CURIE mission comprises two near-identical 3U CubeSats designed to explore low-frequency radio interferometry in space. These CubeSats will study solar radio bursts by maintaining a 1-3 km separation post-deployment, contributing to the understanding of heliospheric space weather and serving as a proof of concept for future space-based interferometry observatories.
Spacemanic’s GRBBeta, a 2U CubeSat, acts as a tech demonstration for the future CAMELOT constellation, aiming to detect and localize gamma-ray bursts from space. Managed by Spacemanic and led by the Technical University of Košice, this mission tests new subsystems, including an advanced GNSS positioning module and a radio modem for instant telemetry.
The successful launch of Ariane 6 represents a significant milestone for the European space industry, heralding a new era of enhanced access to space for European entities. Ariane 6 is designed to offer flexibility and cost-efficiency, making it an attractive option for various space missions. Through supporting this historic launch, Exolaunch reinforces its dedication to fostering growth and innovation in Europe’s space sector.
"Exolaunch is honored to have been part of the Ariane 6 maiden flight, working alongside Arianespace, ESA, and CNES to provide our customers with dependable access to space,” remarked Jeanne Allarie, chief commercial officer at Exolaunch. “We also extend congratulations to ESA, NASA, and Spacemanic on their successful satellite deployments. We are proud to support these innovative missions and look forward to the scientific and technological advancements they will each bring. This launch is not only a testament to the technical prowess and collaborative spirit of the European space community, but also a stepping stone towards a more robust, competitive European presence in the global space industry. We look forward to the opportunity to support future Ariane 6 launches and ensure that Europe remains at the forefront of space exploration.”
About Exolaunch
Exolaunch (Germany, USA) is a global leader in launch mission integration and deployment technologies. With a decade of flight heritage and nearly 400 satellites launched across 29 missions to date, Exolaunch leverages industry insight to tailor turnkey solutions that meet customer needs and respond to market trends. Exolaunch fulfills launch contracts for industry leaders, the world's most innovative start-ups, research institutions, government organizations, and international space agencies. The company develops and manufactures its own flight-proven and industry-leading small satellite separation systems, with the fastest-growing heritage on the market. Exolaunch promotes safe, sustainable, and responsible use of space and is committed to making space accessible for all.
For more information, please visit www.exolaunch.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709995719/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom